France

Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal Melanoma Patients (PLUME)

This Phase II, single-centre trial aims to evaluate the combination of pembrolizumab and lenvatinib in patients with metastatic uveal melanoma (UM). Researchers suspect that prior treatment with Tebentafusp may influence the effectiveness of anti-PD-1 therapies. To investigate this, the study will include two separate groups: Both cohorts will receive the same treatment, and the study […]

Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal Melanoma Patients (PLUME) Read More »

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilising monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Read More »

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long term follow-up (up to 3 years) to

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Read More »

Skip to content